Lactobacillus casei L.Cassi21 with treatment effect on diarrhea and application thereof

Abstract

The invention relates to the technical field of microorganisms, and particularly relates to lactobacillus casei L.Cassi21 with a treatment effect on diarrhea and application thereof. The lactobacillus casei L.Cassi21 is classified and named as lactobacillus casei, has a preservation number of CGMCC NO.21373, and is preserved on December 14, 2020, is preserved in the China General Microbiological Culture Collection Center located at No.3, Yard 1, West Beichen Road, Chaoyang District, Beijing. The lactobacillus casei L.Cassi21 can be used for preparing a product for treating diarrhea. After the product prepared from the lactobacillus casei L.Cassi21 is taken, the thallus can enter intestinal tracts through digestive tracts to inhibit pathogenic bacteria and colonize the intestinal tracts, so that environmental flora balance can be kept, diarrhea symptoms can be improved, and the diarrhea recurrence risk can be reduced.

Description

technical field

[0001] The invention relates to the technical field of microorganisms, in particular to Lactobacillus casei L. Casei21 which has a therapeutic effect on diarrhea and an application thereof. Background technique

[0002] Diarrhea is a common symptom, which refers to the frequency of defecation significantly exceeding the frequency of usual habits, thin fecal matter, increased water content, daily defecation volume exceeding 200g, or containing undigested food or pus, blood, and mucus. Diarrhea is often accompanied by symptoms such as urgency to defecate, anal discomfort, and incontinence. Diarrhea can be treated with medication. Although drug therapy has obvious effects, its disadvantages are also obvious. For example, the use of drugs containing antibiotics will kill both pathogenic and beneficial bacteria, temporarily relieve symptoms, and is not conducive to later recovery. Long-term use will cause pathogenic bacteria to develop drug resistance. And in th...

Examples

Embodiment 1

[0019] Example 1 Separation and purification of strains

[0020] Feces samples were taken from breastfeeding infants with no family genetic disease history in Bama Yao Autonomous County, Guangxi. During the sampling process, gloves were worn for disinfection to avoid contact with samples to prevent contamination. Immediately after the sample was taken out, it was stored in a refrigerated box and numbered and recorded.

[0021] The sample liquid was diluted tenfold, and 100 μL of each gradient was evenly spread on the MRS solid plate medium. The components and contents of the MRS solid plate medium were as follows:

[0022] Peptone 10g, beef powder 5g, yeast powder 4g, K 2 HPO 4 •7H 2 O 2g, triammonium citrate 2g, CH 3 COONa•3H 2 O5g, glucose 20g, Tween 80 1mL, MgSO 4 •7H 2 O 0.2g, MnSO 4 • 4H 2 O 0.05g, agar 15g and distilled water 1000mL.

[0023] Then it was taken out and placed in an anaerobic tank, and incubated overnight at 37°C. On the next day, colonies of var...

Embodiment 2

[0025] Embodiment 2 strain identification

[0026] Appraisal Unit: Sangon Bioengineering (Shanghai) Co., Ltd.

[0027] Primer sequences: 27F (5'-AGAGTTTGATCMTGGCTCAG-3'), 1492R (5'-GGTTACCTTGTTACGACTT-3').

[0028] 菌种序列:TGCAAGTCGAACGAGTTTTGGTCGATGAACGGTGCTTGCACTGAGATTCGACTTAAAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGCAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTA...

Embodiment 3

[0030] Embodiment 3 product preparation

[0031] A product for treating diarrhea, comprising Lactobacillus casei powder and isomaltooligosaccharide, wherein the Lactobacillus casei powder is prepared according to the following preparation method:

[0032] (1) Lactobacillus casei L.Casei21 was inoculated into MRS liquid medium at a volume fraction of 1% inoculum and cultured at 37°C. The components and contents of MRS liquid medium were as follows:

[0033] Peptone 10g, beef powder 5g, yeast powder 4g, K 2 HPO 4 •7H 2 O 2g, triammonium citrate 2g, CH 3 COONa•3H 2 O5g, glucose 20g, Tween 80 1mL, MgSO 4 •7H 2 O 0.2g, MnSO 4 • 4H 2 O 0.05g and distilled water 1000mL;

[0034] (2) centrifuging and vacuum freeze-drying the cultured L.Casei21 bacterial liquid to obtain Lactobacillus casei bacterial powder;

[0035] Adjust the ratio of Lactobacillus casei powder and isomaltooligosaccharide to prepare Lactobacillus casei L.Casei21 viable counts of 5 billion / g, 10 billion / g, 1...

technical field

[0001] The invention relates to the technical field of microorganisms, in particular to Lactobacillus casei L. Casei21 which has a therapeutic effect on diarrhea and an application thereof. Background technique

[0002] Diarrhea is a common symptom, which refers to the frequency of defecation significantly exceeding the frequency of usual habits, thin fecal matter, increased water content, daily defecation volume exceeding 200g, or containing undigested food or pus, blood, and mucus. Diarrhea is often accompanied by symptoms such as urgency to defecate, anal discomfort, and incontinence. Diarrhea can be treated with medication. Although drug therapy has obvious effects, its disadvantages are also obvious. For example, the use of drugs containing antibiotics will kill both pathogenic and beneficial bacteria, temporarily relieve symptoms, and is not conducive to later recovery. Long-term use will cause pathogenic bacteria to develop drug resistance. And in th...

Examples

Embodiment 1

[0019] Example 1 Separation and purification of strains

[0020] Feces samples were taken from breastfeeding infants with no family genetic disease history in Bama Yao Autonomous County, Guangxi. During the sampling process, gloves were worn for disinfection to avoid contact with samples to prevent contamination. Immediately after the sample was taken out, it was stored in a refrigerated box and numbered and recorded.

[0021] The sample liquid was diluted tenfold, and 100 μL of each gradient was evenly spread on the MRS solid plate medium. The components and contents of the MRS solid plate medium were as follows:

[0022] Peptone 10g, beef powder 5g, yeast powder 4g, K 2 HPO 4 •7H 2 O 2g, triammonium citrate 2g, CH 3 COONa•3H 2 O5g, glucose 20g, Tween 80 1mL, MgSO 4 •7H 2 O 0.2g, MnSO 4 • 4H 2 O 0.05g, agar 15g and distilled water 1000mL.

[0023] Then it was taken out and placed in an anaerobic tank, and incubated overnight at 37°C. On the next day, colonies of var...

Embodiment 2

[0025] Embodiment 2 strain identification

[0026] Appraisal Unit: Sangon Bioengineering (Shanghai) Co., Ltd.

[0027] Primer sequences: 27F (5'-AGAGTTTGATCMTGGCTCAG-3'), 1492R (5'-GGTTACCTTGTTACGACTT-3').

[0028] 菌种序列:TGCAAGTCGAACGAGTTTTGGTCGATGAACGGTGCTTGCACTGAGATTCGACTTAAAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGCAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTA...

Embodiment 3

[0030] Embodiment 3 product preparation

[0031] A product for treating diarrhea, comprising Lactobacillus casei powder and isomaltooligosaccharide, wherein the Lactobacillus casei powder is prepared according to the following preparation method:

[0032] (1) Lactobacillus casei L.Casei21 was inoculated into MRS liquid medium at a volume fraction of 1% inoculum and cultured at 37°C. The components and contents of MRS liquid medium were as follows:

[0033] Peptone 10g, beef powder 5g, yeast powder 4g, K 2 HPO 4 •7H 2 O 2g, triammonium citrate 2g, CH 3 COONa•3H 2 O5g, glucose 20g, Tween 80 1mL, MgSO 4 •7H 2 O 0.2g, MnSO 4 • 4H 2 O 0.05g and distilled water 1000mL;

[0034] (2) centrifuging and vacuum freeze-drying the cultured L.Casei21 bacterial liquid to obtain Lactobacillus casei bacterial powder;

[0035] Adjust the ratio of Lactobacillus casei powder and isomaltooligosaccharide to prepare Lactobacillus casei L.Casei21 viable counts of 5 billion / g, 10 billion / g, 1...

Images